Plus Therapeutics Announces Key RNL Development and cGMP Drug Manufacturing Collaboration Agreements (GlobeNewswire) - May 4, 2021 - "Plus Therapeutics, Inc...announced two collaboration agreements to support its process development and analytical chemistry activities for the cGMP manufacturing of Rhenium NanoLiposome (RNL™), the Company's lead investigational asset in clinical development for recurrent glioblastoma. Plus Therapeutics signed a pre-clinical, clinical, and process development agreement with Invicro LLC (Invicro)...Under this agreement, Invicro will characterize the current manufacturing process and develop in-process manufacturing controls for the RNL™ active pharmaceutical ingredient (API) and final drug product and provide future clinical trial imaging support and drug development consulting. In addition, Plus Therapeutics entered into an agreement with Eurofins BioPharma Inc...a market leader in analytical chemistry for discovery pharmacology and advanced materials sciences."
Licensing / partnership • Glioblastoma • Oncology
|